Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative

(2019) Mohammad Y. Zaidi et al.   ANNALS OF SURGICAL ONCOLOGY

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

(2019) William D. Tap et al.   JOURNAL OF CLINICAL ONCOLOGY

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2018) P G Casali et al.   ANNALS OF ONCOLOGY

Soft Tissue and Uterine Leiomyosarcoma

(2018) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

(2018) Margaret von Mehren et al.   Journal of the National Comprehensive Cancer Network

Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas

(2018) Carlo Lucchesi et al.   JAMA Oncology

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

(2017) Beatrice Seddon et al.   LANCET ONCOLOGY

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

(2017) Alessandro Gronchi et al.   LANCET ONCOLOGY

Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS).

(2017) U. Bitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

(2016) Javier Martin-Broto et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

Clinically Relevant Molecular Subtypes in Leiomyosarcoma

(2015) X. Guo et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study

(2015) Martee L. Hensley et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

(2015) Patricia Pautier et al.   LANCET ONCOLOGY

Lessons Learned From the Study of 10,000 Patients With Soft Tissue Sarcoma

(2014) Murray F. Brennan et al.   ANNALS OF SURGERY

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

(2014) Ian Judson et al.   LANCET ONCOLOGY

Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas

(2012) P. G. Casali   ANNALS OF ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples

(2011) Jeremy A. Rassen et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study

(2011) Xavier García-del-Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses

(2011) Jeremy A. Rassen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution

(2010) Alessandro Gronchi et al.   ANNALS OF SURGERY

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

(2009) Stefan Sleijfer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling

(2009) A H Beck et al.   ONCOGENE